Background: Type 2 diabetes (T2D) remains a major global public health problem. This complex metabolic disorder can lead to various complications, including cardiovascular diseases (leading cause of death) in T2D. Among the biochemical markers associated with increased risk for cardiovascular disease, homocysteine is currently one of the predictive markers under evaluation. We investigate the link between hyperhomocysteinemia and diabetes complications in DT2 population in Brazzaville. Methodology: We conducted a cross-sectional analytical study, from October to December 2022. One hundred and fifty participants were included, 100 patients T2D (34 with complications, 33 with comorbidities, 33 without), and 50 patients controls. Sociodemographic and clinical characteristics were collected. Homocysteine (Hcy) serum levels were measured using Sandwich ELISA method. Results: Study population was composed of 50% males and 50% females with sex ratio of 1; mean age was 52.2 ± 10.8 years (30 - 83). The prevalence of hyperhomocysteinemia (HHcy) was 36% (20% moderate Hcy, 15% intermediate and 1% severe). Mean Hcy concentration was 31.9 μmol/l (18 - 103). Age, gender and physical inactivity were strongly correlated to Hcy (OR of 3.5; 9.4 and 3 respectively). Multivariate analysis showed that HHcy was a risk accelerator for degenerative complications (stroke: OR = 6.2; ischemic heart disease: 4.9; neuropathy: 9.2; retinopathy: 4.5 and peripheral arterial disease: 4.9). Conclusion: These findings suggest that hyperhomocysteinemia can be considered as a predictive marker to be taken into account in targeting cardiovascular risk in Congolese subjects with T2D.
References
[1]
CDC (2020) National Diabetes Statistics Report 2020. Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, 12-15.
[2]
Attia, A., Douki, W., et al. (2005) Homocysteine: Metabolism, Dosage and Implications in Human Pathology. Feuillets de Biologie, 266, 33-42.
[3]
Mtiraoui, N., Ezzidi, I., et al. (2007) MTHFR C677T and A1298C Gene Polymorphisms and Hyperhomocysteinemia as Risk Factors of Diabetic Nephropathy in Type 2 Diabetes Patients. Diabetes Research and Clinical Practice, 75, 99-106. https://doi.org/10.1016/j.diabres.2006.05.018
[4]
Ukinc, K., Ersoz, H.O., et al. (2009) Methyltetrahydrofolate Reductase C677T Gene Mutation and Hyperhomocysteinemia as a Novel Risk Factor for Diabetic Nephropathy. Endocrine, 36, 255-261. https://doi.org/10.1007/s12020-009-9218-7
[5]
Oishi, K., Nagake, Y., et al. (2000) The Significance of Serum Homocysteine Levels in Diabetic Patients on Haemodialysis. Nephrology Dialysis Transplantation, 15, 851-855. https://doi.org/10.1093/ndt/15.6.851
[6]
Agulló-Ortuño, M.T., Albaladejo, M.D., et al. (2002) Plasma Homocysteine Concentration and Its Relationship with Complications Associated with Diabetes Mellitus. Clinica Chimica Acta, 326, 105-112. https://doi.org/10.1016/S0009-8981(02)00287-5
[7]
Mazza, A., Bossone, E., Mazza, F. and Distante, A. (2005) Reduced Serum Homocysteine Levels in Type 2 Diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 15, 118-124. https://doi.org/10.1016/j.numecd.2004.03.001
[8]
Amouzou, E.K., Chabi, N.W., et al. (2004) High Prevalence of Hyperhomocysteinemia Related to Folate Deficiency and the 677C→T Mutation of the Gene Encoding Methylenetetrahydrofolate Reductase in Coastal West Africa. The American Journal of Clinical Nutrition, 79, 619-624. https://doi.org/10.1093/ajcn/79.4.619
[9]
Kombate, D., Assogba, K., et al. (2010) Hyperhomocysteinemia among Ischemic Stroke Victims in the Teaching Hospital of Lomé. Annales de Biologie Clinique, 68, 669-673. (In French)
[10]
Djohan, Y.F., Koffi, K.G., et al. (2013) Interet du dosage de l’homocystéine; de la vitamine B12 et de l’acide folique au cours des maladies cardiovasculaires en Côte d’Ivoire. Revue du CAMES: Science de la santé 1: 2.
[11]
Cisse, F., Diallo, F., Diatta, A., et al. (2015) Hyperhomocysteinemia and Type 2 Diabetes. Revue du CAMES: Science de la santé, 3, 9-12.
[12]
Grunitzky, E., Balogou, A., et al. (2008) Homocysteinemia and Ischemic Cerebral Vascular Accidents at the CHU Campus of Lomé. American Journal of Nursing Science, 27, 2, 3-6.
[13]
Ferjani, W., Bouzid, K., et al. (2011) Relationship between Blood Homocysteine and Creatinine in Patients with Metabolic Syndrome and Association between Hyperhomocysteinemia and Metabolic Syndrome. Immuno-Analyse & Biologie Spécialisée, 26, 244-249. https://doi.org/10.1016/j.immbio.2011.10.004
[14]
Mabrouka, E.O., Aouni, Z., Ouertani, H., Mazigh, C. and Machghoul, S. (2010) Effect of Lipopenic and Hypotensive Treatment on Homocysteine Levels in Type 2 Diabetics. Vascular Health and Risk Management, 6, 327-332. https://doi.org/10.2147/VHRM.S8240
[15]
Chadli-Chaieb, M., Marmouch, H., Mtiraoui, N., Mahjoub, T. and Chaieb, L. (2008) C677T and A1298C Polymorphism of the Methylenetetrahydrofolate Reductase (MTHFR) Gene and Cardiovascular Risk in Type 2 Diabetics. Diabetes & Metabolism, 34, H55. (In French) https://doi.org/10.1016/S1262-3636(08)72957-4
[16]
Fekih-Mrissa, N., et al. (2017) Methylenetetrahydrofolate Reductase (MTHFR) (C677T and A1298C) Polymorphisms and Vascular Complications in Patients with Type 2 Diabetes. Canadian Journal of Diabetes, 41, 366-371. https://doi.org/10.1016/j.jcjd.2016.11.007
[17]
Ducros, V., Candito, M., et al. (2001) Plasma Homocysteine Measurement: A Study of Pre-Analytical Variation Factors for Conditions for Total Plasma Homocysteine Concentration. Annales de Biologie Clinique, 59, 33-39. (In French)
[18]
Zhang, S., Bai, Y.-Y., et al. (2014) Association between Serum Homocysteine and Arterial Stiffness in the Elderly: A Community Study. Journal of Geriatric Cardiology, 11, 32-38.
[19]
Ganguly, P. and Alam, S.F. (2015) Role of Homocysteine in the Development of Cardiovascular Disease. Nutrition Journal, 14, Article No. 6. https://doi.org/10.1186/1475-2891-14-6
[20]
Buysschaert, M., Gala, J.L., Bessomo, A. and Hermans, M.P. (2004) C677T Methylene-Tetrahydrofolate Reductase Mutation in Type 2 Diabetic Patients with and without Hyperhomocysteinaemia. Diabetes & Metabolism, 30, 349-354. https://doi.org/10.1016/S1262-3636(07)70127-1
[21]
Rudy, A., Kowalska, I., Strączkowski, M. and Kinalska, I. (2005) Homocysteine Concentrations and Vascular Complications in Patients with Type 2 Diabetes. Diabetes & Metabolism, 31, 112-117. https://doi.org/10.1016/S1262-3636(07)70176-3
[22]
Ndrepepa, G., Kastrati, A., et al. (2008) Circulating Homocysteine Levels in Patients with Type 2 Diabetes Mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 18, 66-73. https://doi.org/10.1016/j.numecd.2006.03.007
[23]
Otmane, A., Makrelouf, M., et al. (2007) Total Homocysteine Levels in Type 2 Diabetic Patients. Revue Francophone des Laboratoires, 396, 21-24. https://doi.org/10.1016/S1773-035X(07)80418-7
[24]
Chang, Y., Li, Y., et al. (2017) The Prevalence of Hypertension Accompanied by High Homocysteine and its Risk Factors in a Rural Population: A Cross-Sectional Study from Northeast China. International Journal of Environmental Research and Public Health, 14, Article No. 376. https://doi.org/10.3390/ijerph14040376
[25]
Selhlub, J., Jacques, P.F., Wilson, P.W.F., Rush, D. and Rosenberg, I.H. (1995) Vitamin Status and Intake as Primary Determinants of Homocysteinemia in Elderly Population. JAMA, 270, 2693-2698. https://doi.org/10.1001/jama.1993.03510220049033
[26]
Krauss, R.M. (2004) Lipids and Lipoproteins in Patients with Type 2 Diabetes. Diabetes Care, 27, 1496-504. https://doi.org/10.2337/diacare.27.6.1496
[27]
Diakoumopoulou, E., Tentolouris, N., et al. (2005) Plasma Homocysteine Levels in Patients with Type 2 Diabetes in a Mediterranean Population: Relation with Nutritional and Other Factors. Nutrition, Metabolism and Cardiovascular Diseases, 15, 109-117. https://doi.org/10.1016/j.numecd.2004.01.001
[28]
Chellak, S., Bigaillon, C., et al. (2005) Correlation Results Between Plasma Homocysteine, Metabolic Syndrome Components and Cardiovascular Risk Markers in 2045 French Military Subjects: EPIMIL Cohort. Immuno-Analyse & Biologie Spécialisée, 20, 169-172. https://doi.org/10.1016/j.immbio.2005.03.002
[29]
Belkhair, J., Chellak, S., et al. (2019) Hyperhomocysteinemia in a Type 2 Diabetic Population: Prevalence and Its Association with Clinico-Biological Parameters. Médecine des Maladies Métaboliques, 13, 556-560. https://doi.org/10.1016/S1957-2557(19)30172-5
[30]
Faeh, D., Chiolero, A. and Paccaud, F. (2006) Homocysteine as a Risk Factor for Cardiovascular Disease: Should We (Still) Worry About? Swiss Medical Weekly, 136, 745-756.
[31]
Bostom, A.G., Rosenberg, I.H., et al. (1999) Nonfasting Plasma Total Homocysteine Levels and Stroke Incidence in Elderly Persons: The Framingham Study. Annals of Internal Medicine, 131, 352-355. https://doi.org/10.7326/0003-4819-131-5-199909070-00006
[32]
Mabchour, A.E., Agueh, V. and Delisle, H. (2010) Determinants and Relationship of Homocysteinemia with Cardiometabolic Risk Factors. A Study in Benin, West Africa. La Presse Médicale, 39, 238-246. https://doi.org/10.1016/j.lpm.2010.03.024
[33]
Goïta, Y., Barca, J., et al. (2020) Multiparametric Biochemical Analysis Revealing an Increase of Homocysteinemia and NT-proBNP in Hypertensive Patients Living in Bamako (Mali). Pan African Medical Journal, 35, Article 10. https://doi.org/10.11604/pamj.2020.35.10.18821
[34]
Sundstrom, J., Sullivan, L., et al. (2003) Plasma Homocysteine, Hypertension Incidence, and Blood Pressure Tracking: The Framingham Heart Study. Hypertension, 42, 1100-1105. https://doi.org/10.1161/01.HYP.0000101690.58391.13
[35]
Toole, F.J. and Jack, C.R. (2002) Foods (and Vitamins) for Thought. Neurology, 58, 1449-1450. https://doi.org/10.1212/WNL.58.10.1449
[36]
Meigs, J.B., Jacques, P.F., et al. (2001) Fasting Plasma Homocysteine Levels in the Insulin Resistance Syndrome: The Framingham Offspring Study. Diabetes Care, 24, 1403-1410. https://doi.org/10.2337/diacare.24.8.1403
[37]
Guilland, J.-C., Favier, A., de Courcy, G.P., Galan, P. and Hercberg, S. (2003) Hyperhomocysteinemia: An Independent Risk Factor or a Simple Marker of Vascular Disease?: 2. Epidemiological Data. Pathologie Biologie, 51, 111-121. https://doi.org/10.1016/S0369-8114(03)00105-6
